MedPath

Immediate-access Arteriovenous Versus Standard Arteriovenous Grafts in Hemodialysis Patients

Not Applicable
Completed
Conditions
Hemodialysis Access Failure
Interventions
Procedure: Arteriovenous Grafts
Registration Number
NCT04388397
Lead Sponsor
Egyptian Biomedical Research Network
Brief Summary

Arteriovenous fistulae (AVF) are considered the main access for hemodialysis (HD). Arteriovenous grafts (AVGs) are an alternative access modality in patients with exhausted native venous access. Immediate-access arteriovenous grafts (IAAVGs) is a new modality in which dialysis can be started immediately to avoid complications of central venous catheters.

Detailed Description

The study aimed to evaluate and compare patency rate and complications of standard arteriovenous grafts (SAVGs) and immediate-access arteriovenous grafts (IAAVGs) in end stage renal disease (ESRD) patients for one year after the intervention. Patients were randomly divided into two groups: SAVGs group and IAAVGs group. Patients with ESRD with no chance for native AVF were examined clinically and by duplex ultrasonography preoperatively. Follow up was for one year. Primary end points were the success rate, complications rate (hematoma, pseudo-aneurysm, graft site infection, systemic bacteremia), time of first cannulation. Secondary end points were primary and secondary patency within one year.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
477
Inclusion Criteria
  • Adult hemodialysis patients
Exclusion Criteria
  • Significant cardiorespiratory comorbidities.
  • Peripheral vascular disease.
  • Pregnancy or lactation.
  • Severe bleeding disorders.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Immediate-access Arteriovenous GraftsArteriovenous GraftsImmediate-access Arteriovenous Grafts as a vascular access for hemodialysis patients
Standard Arteriovenous GraftsArteriovenous GraftsStandard Arteriovenous Grafts as a vascular access for hemodialysis patients
Primary Outcome Measures
NameTimeMethod
Success rate24 hours

successful graft procedure

Primary Patency1 year

Patency of hemodialysis access

Secondary Outcome Measures
NameTimeMethod
Complications rate1 year

Any graft complications

Trial Locations

Locations (2)

Faculty of Medicine

🇪🇬

Zagazig, Egypt

Faculty of Medicine, Zagazig University

🇪🇬

Zagazig, Egypt

© Copyright 2025. All Rights Reserved by MedPath